PDF(Pubmed)
Abstract：
BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for BRAF fusions.
摘要：
BRAF基因已被确定为致癌驱动因子和各种恶性肿瘤的潜在靶标。BRAF融合是罕见频率的BRAF改变的一种亚型。这里,我们首先报道了1例既往接受SND1-BRAF从头融合治疗的晚期肺腺癌患者,该患者对MAK抑制剂曲美替尼实现部分应答.我们还提供了关于BRAF融合的靶向治疗的文献综述。
